Source comparison
CJC-1295 Results After 1 Month: Research-Grade Comparison
Sleep Quality (Deep Sleep Duration) +10–15% vs baseline +15–25% vs baseline Measurable via wearable EEG trackers Most consistent early indicator of GHRH receptor activation Serum IGF-1 Elevation Minimal (5–10% above baseline) +20–40% above baseline Normal rang
This comparison does not assign a generated winner or score.
- Sleep Quality (Deep Sleep Duration)
- +10–15% vs baseline
- +15–25% vs baseline
- Measurable via wearable EEG trackers
- Most consistent early indicator of GHRH receptor activation
- Serum IGF-1 Elevation
- Minimal (5–10% above baseline)
- +20–40% above baseline
- Normal range: 115–307 ng/mL (age-dependent)
- Confirms biological response; low responders show <15% increase
- Lean Mass Gain (DEXA)
- Not detectable
- 0.5–1.5 lbs
- Margin of error: ±1.5 lbs
- Statistically insignificant at 4 weeks; meaningful gains emerge weeks 8–12
- Fat Mass Reduction (DEXA)
- 1–2 lbs
- GH-mediated lipolysis requires sustained IGF-1 elevation over 6–8 weeks
- Recovery Time (DOMS Resolution)
- 15–20% faster
- 20–30% faster
- Subjective but consistent across protocols
- Reflects accelerated collagen synthesis and tissue repair
- Skin Hydration & Elasticity
- Minimal change
- Noticeable improvement
- Dermal HA synthesis peaks week 3–4
- Early cosmetic marker; precedes body composition changes by 4–6 weeks
- CJC-1295 without DAC (Modified GRF 1-29) requires more frequent dosing—typically 100–200 mcg three times daily pre-meal—and produces more pronounced GH spikes but shorter duration of effect. CJC-1295 DAC allows twice-weekly dosing at 1–2 mg per injection, maintaining elevated baseline GH without the same peak amplitude. The choice depends on protocol goals: DAC is more convenient for sustained anabolic signaling; non-DAC is preferred when mimicking natural pulsatility matters (e.g., anti-aging or recovery-focused protocols).